Technical Analysis for EBS - Emergent Biosolutions, Inc.

Grade Last Price % Change Price Change
grade A 135.275 0.25% 0.34
EBS closed up 4.14 percent on Thursday, August 13, 2020, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical EBS trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.25%
Wide Bands Range Expansion 0.25%
Overbought Stochastic Strength 0.25%
180 Bullish Setup Bullish Swing Setup 4.40%
Multiple of Ten Bearish Other 4.40%
Wide Bands Range Expansion 4.40%
Overbought Stochastic Strength 4.40%
1,2,3 Pullback Bullish Bullish Swing Setup 10.58%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 10.58%
Wide Bands Range Expansion 10.58%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Emergent BioSolutions, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. It markets BioThrax, an FDA licensed vaccine for the prevention of anthrax disease; and RSDL (decontamination lotion) product for removal or neutralization of chemical warfare agents from the skin. The company's development pipeline includes Anthrivig (Human Anthrax Immunoglobulin), a polyclonal anthrax therapeutic candidate; PreviThrax, a recombinant anthrax vaccine candidate, NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant); BioThrax with a novel adjuvant; and Thravixa (Fully Human Anthrax Monoclonal Antibody), a therapeutic being studied for use against symptomatic anthrax infection. In addition, it develops TRU-016, a humanized anti-CD37 therapeutic candidate, based on its ADAPTIR (Modular Protein Technology) platform that is in Phase I/II clinical trials to treat chronic lymphocytic leukemia. Further, the company develops preclinical product candidates targeted for solid tumors, inflammatory bowel disease, graft versus host disease, rheumatoid arthritis, and a human vaccine to protect against influenza caused by a range of circulating H5 influenza strains. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Rockville, Maryland.
Medicine Pharmaceutical Drugs Solid Tumors Rheumatoid Arthritis Influenza Vaccination Inflammatory Bowel Disease FDA Blood Plasma Chronic Lymphocytic Leukemia Vaccines Biological Warfare Anthrax Chemical Warfare Agents Preclinical Preclinical Product

Is EBS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 137.61
52 Week Low 39.11
Average Volume 1,045,640
200-Day Moving Average 69.46
50-Day Moving Average 92.41
20-Day Moving Average 110.64
10-Day Moving Average 126.10
Average True Range 7.08
ADX 40.08
+DI 39.34
-DI 13.46
Chandelier Exit (Long, 3 ATRs ) 116.38
Chandelier Exit (Short, 3 ATRs ) 107.53
Upper Bollinger Band 143.81
Lower Bollinger Band 77.46
Percent B (%b) 0.87
BandWidth 59.97
MACD Line 11.55
MACD Signal Line 9.75
MACD Histogram 1.8
Fundamentals Value
Market Cap 5.55 Billion
Num Shares 41.1 Million
EPS 1.57
Price-to-Earnings (P/E) Ratio 85.95
Price-to-Sales 3.22
Price-to-Book 2.65
PEG Ratio 1.56
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 142.31
Resistance 3 (R3) 141.83 138.91 141.08
Resistance 2 (R2) 138.91 137.03 139.14 140.67
Resistance 1 (R1) 136.92 135.87 137.92 137.40 140.26
Pivot Point 134.00 134.00 134.49 134.23 134.00
Support 1 (S1) 132.01 132.12 133.01 132.49 129.62
Support 2 (S2) 129.09 130.96 129.32 129.21
Support 3 (S3) 127.10 129.09 128.80
Support 4 (S4) 127.58